EP4255397

ORAL FORMULATIONS OF TENAPANOR

  • Status:
    EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á Íslandi
  • EP appl. date:
    6.12.2021
  • EP published:
    18.2.2026
  • EP application number:
    21835087.4
  • Max expiry date:
    5.12.2041
  • Expiry date:
    5.12.2026
  • Title in English:
    ORAL FORMULATIONS OF TENAPANOR
  • Language of the patent:
    English

Timeline

Today
6.12.2021EP application
18.2.2026EP Publication
5.12.2026Expires

Owner

  • Name:
    Ardelyx, Inc.
  • Address:
    34175 Ardenwood Blvd., Fremont, California 94555, US
  • Name:
    AstraZeneca AB
  • Address:
    Forskargatan 18, 151 85 Södertälje, SE

Inventor

  • Name:
    GUNNARSSON, Cecilia
  • Address:
    431 50 Mölndal, SE
  • Name:
    SWENSON, Magnus
  • Address:
    151 85 Sodertélje, SE
  • Name:
    MATIC, Hanna
  • Address:
    151 85 Sodertélje, SE
  • Name:
    SALOMONSSON, John
  • Address:
    151 85 Sodertélje, SE
  • Name:
    KARLSSON, Eva
  • Address:
    151 85 Sodertélje, SE

Priority

  • Number:
    202063199078 P
  • Date:
    4.12.2020
  • Country:
    US

Classification

  • Categories:
    A61K 9/16, A61K 9/20, A61K 31/00

Upload documents